Skip to main content

Table 1 Characteristics of patients and tumors

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

  N = 56 (%)
Median Age (years, range) 68 (42–88)
Gender
 Male 29 (52)
 Female 27 (48)
ECOG Performance Status
 0 3 (5)
 1 41 (73)
 2 12 (21)
Primary tumor location
 Head 28 (50)
 Body 11 (20)
 Tail 12 (21)
 Body and tail 5 (9)
Stage at start of treatment
 III 2 (4)
 IV 54 (96)
Metastatic sites
 Liver 41 (73)
 Peritoneum 16 (29)
 Lung 15 (27)
 Distant lymph nodes 18 (32)
 Other 10 (18)
Number of metastatic sites
 1 29 (52)
 2 8 (14)
 3 or more 16 (29)
Prior lines of advanced disease therapy
 0 4 (7)
 1 20 (36)
 2 21 (38)
 3 or more 11 (20)